Drug intelligence / Profile preview

STE-006

Development stage: Discontinued
Lead developer: Harrow
Modality: Small Molecules
Administration: Ophthalmic, Otic

Overview

STE-006 is a discontinued topical anti-infective drug candidate that was being developed by Stowe Pharmaceuticals, a subsidiary of Harrow Health, for ophthalmic and otic indications, primarily non-specific conjunctivitis. The asset was originally licensed from TGV-Health. Following preclinical in vitro and in vivo studies at a U.S. academic research institution that failed to replicate earlier efficacy data against ophthalmic pathogens, Harrow Health terminated the license agreement in May 2021 and discontinued further development of the candidate.

Beyond the preview

Go deeper on STE-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STE-006.

Explore the full profile